|
Volumn 38, Issue 7, 2006, Pages 245-246
|
Clinical experience with recombinant pollen allergens
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALLERGEN;
ALLERGOID;
ALLERGOVIT;
ALUMINUM HYDROXIDE;
BET V 1;
POLLEN ANTIGEN;
UNCLASSIFIED DRUG;
ALLERGIC DISEASE;
ALLERGIC RHINITIS;
ANTIBODY RESPONSE;
ARTICLE;
BASOPHIL;
BIRCH;
CELL ACTIVATION;
CHROMATOGRAPHY;
CLINICAL FEATURE;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG MANUFACTURE;
DRUG MECHANISM;
DRUG SAFETY;
DRUG SYNTHESIS;
DRUG TOLERABILITY;
GRASS POLLEN;
HUMAN;
IMMUNOTHERAPY;
MOLECULAR CLONING;
NOSE PROVOCATION TEST;
PHLEUM PRATENSE;
PHYSICAL CHEMISTRY;
PROVOCATION TEST;
PURIFICATION;
QUALITY OF LIFE;
T LYMPHOCYTE ACTIVATION;
TREATMENT RESPONSE;
ALLERGENS;
DESENSITIZATION, IMMUNOLOGIC;
HUMANS;
HYPERSENSITIVITY, IMMEDIATE;
POLLEN;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIALS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RECOMBINANT PROTEINS;
TREATMENT OUTCOME;
|
EID: 33750211813
PISSN: 03979148
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (2)
|
References (5)
|